abs273.txt	background		regorafenib		a	multikinase	inhibitor	that	inhibits	angiogenesis	growth		and	proliferation		prolongs	survival	as	monotherapy	in	patients	withrefractory	colorectal	cancer		this	international		double-blind	placebo-controlled		multicenter	trial	assessed	the	efficacy	of	regorafenib	withfolinic	acid		fluorouracil		and	irinotecan	(folfiri)	as	a	second-line	treatmentfor	metastatic	colorectal	cancer	methods		patients	with	metastatic	colorectal	cancer	who	progressed	on	first-lineoxaliplatin	and	fluoropyrimidine	enrolled	at	45	sites	in	the	united	states	andireland		patients		stratified	by	prior	bevacizumab	use		were	randomized	2	1	toregorafenib	or	placebo		the	treatment	consisted	of	folfiri	on	days	1	and	2	anddays	15	and	16	with	160	mg	of	regorafenib	or	placebo	on	days	4	to	10	and	days	18to	24	of	every	28-day	cycle		crossover	was	not	allowed		the	primary	endpoint	wasprogression-free	survival	(pfs)		under	the	assumption	of	a	75%	event	rate		180patients	were	required	for	135	events	to	achieve	90%	power	to	detect	a	hazardratio	(hr)	of	0	65	with	a	1-sided	α	value	of		1	results		one	hundred	eighty-one	patients	were	randomized	(120	toregorafenib-folfiri	and	61	to	placebo-folfiri)	with	a	median	age	of	62	years	among	these		117	(65%)	received	prior	bevacizumab	or	aflibercept		pfs	was	longerwith	regorafenib-folfiri	than	placebo-folfiri	(median		6	1	vs	5	3	months		hr	0	73		95%	confidence	interval	[ci]		0	53-1	01		log-rank	p	=		056)		the	medianoverall	survival	was	not	longer	(hr		1	01		95%	ci		0	71-1	44)		the	response	ratewas	higher	with	regorafenib-folfiri	(34%		95%	ci		25%-44%)	than	placebo-folfiri(21%		95%	ci		11%-33%		p	=		07)		grade	3/4	adverse	events	with	a	>5%	absoluteincrease	from	regorafenib	included	diarrhea		neutropenia		febrile	neutropenia	hypophosphatemia		and	hypertension	conclusions		the	addition	of	regorafenib	to	folfiri	as	second-line	therapy	formetastatic	colorectal	cancer	only	modestly	prolonged	pfs	over	folfiri	alone	cancer	2018		©	2018	american	cancer	society	
